Mirum Pharmaceuticals

Yahoo Finance • 6 days ago

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

On February 17, 2026, Boone Capital Management sold out its entire Cogent Biosciences(NASDAQ:COGT) stake, liquidating 945,042 shares previously worth $13.57 million. What happened According to an SEC filing dated February 17, 2026, Boone... Full story

Yahoo Finance • 6 days ago

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

On February 17, 2026, Boone Capital Management disclosed a new position in Tyra Biosciences(NASDAQ:TYRA), acquiring 398,482 shares worth $10.48 million at quarter’s end. What happened According to a Securities and Exchange Commission (SE... Full story

Yahoo Finance • 11 days ago

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?

What happened According to a U.S. Securities and Exchange Commission (SEC) filing dated February 17, 2026, Boone Capital Management established a new position in HealthEquity by purchasing 212,856 shares. The reported value of the transac... Full story

Yahoo Finance • last month

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., February 11, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of... Full story

Yahoo Finance • 4 months ago

Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $95 and keeps an Overweight rating on the shares. Mirum’s proposed acquisition of Bluejay Therapeutics for $250M in cash, $300M in stock, and $20... Full story

Yahoo Finance • 4 months ago

Mirum Pharmaceuticals To Acquire Bluejay Therapeutics In Rare Liver Disease Expansion

(RTTNews) - Mirum Pharmaceuticals (MIRM) on Monday announced that it has agreed to acquire Bluejay Therapeutics in a deal valued at $620 million in cash and stock, adding brelovitug, a late-stage monoclonal antibody for chronic hepatitis d... Full story

Yahoo Finance • 4 months ago

Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge

Key Points Philadelphia-based Penn Capital Management sold 1.6 million shares of BGC Group during the quarter ended September 30, leading to a net position change estimated at $17.1 million. The third-quarter transaction represented a 1.2... Full story

Yahoo Finance • 5 months ago

Mirum aims for $500M–$510M 2025 revenue as cash flow turns positive and pivotal trial readouts approach

Earnings Call Insights: Mirum Pharmaceuticals (MIRM) Q3 2025 MANAGEMENT VIEW * CEO Christopher Peetz stated that "2025 continues to be an outstanding year for Mirum" and highlighted strong commercial results, pipeline progress, and a s... Full story

Yahoo Finance • 5 months ago

The Math Shows FHLC Can Go To $79

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 7 months ago

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows High Growth Momentum and Technical Breakout Potential

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM [https://www.chartmill.com/stock/quote/MIRM]) has become an interesting candidate for investors using a high growth momentum strategy with technical breakout analysis. This method focuses on finding c... Full story

Yahoo Finance • 7 months ago

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Screens as a High-Growth Momentum Stock Using Minervini Trend Template

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM [https://www.chartmill.com/stock/quote/MIRM]) has appeared as a notable candidate from a screening method that joins Mark Minervini’s Trend Template with a High Growth Momentum (HGM) rating. This two-... Full story

Yahoo Finance • 7 months ago

Mirum Pharma CEO Peetz sells $2.48 million in shares

Mirum Pharmaceuticals (NASDAQ:MIRM) Chief Executive Officer Christopher Peetz sold 40,000 shares of common stock on August 11, 2025, at a price of $62.0, totaling $2.48 million. The transaction was executed under a Rule 10b5-1 trading plan... Full story

Yahoo Finance • 7 months ago

Mirum Pharma CFO Eric Bjerkholt sells $524k in stock

Mirum Pharmaceuticals (NASDAQ:MIRM), a $3.25 billion market cap biopharmaceutical company whose stock has surged over 21% in the past week, reported that Chief Financial Officer Eric Bjerkholt sold 8,000 shares of common stock on August 11... Full story

Yahoo Finance • 8 months ago

Earnings call transcript: Mirum Pharmaceuticals sees revenue boost in Q2 2025

Mirum Pharmaceuticals Inc. reported its Q2 2025 earnings on August 6, showing a notable improvement in its financial results. The company posted an earnings per share (EPS) of -$0.12, significantly beating the forecasted -$0.33. Revenue ca... Full story

Yahoo Finance • 8 months ago

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Surpasses Q2 2025 Estimates with Strong Revenue Growth and Raised Guidance

Mirum Pharmaceuticals Inc (NASDAQ:MIRM [https://www.chartmill.com/stock/quote/MIRM]) reported second-quarter 2025 financial results that exceeded analyst expectations, prompting a positive market reaction in after-hours trading. The compan... Full story

Yahoo Finance • 8 months ago

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Fits Minervini’s Trend Template with Strong Growth Momentum

Mirum Pharmaceuticals Inc (NASDAQ:MIRM [https://www.chartmill.com/stock/quote/MIRM]) has become a possible choice for investors using Mark Minervini’s trend-following approach along with high-growth momentum screening. The Minervini Trend... Full story

Yahoo Finance • 8 months ago

Mirum Hits All-Time High - Is There More Upside Ahead?

(RTTNews) - Mirum Pharmaceuticals Inc. (MIRM) has kicked off the year with commercial growth and successful pipeline milestones, propelling its shares to an all-time high of $53. The company has three approved ultra-rare medicines and 4 c... Full story

Yahoo Finance • 3 years ago

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

• Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments • Mirum has acquired Travere’s rights and assets related to Cholbam® and Chenodal® • Advances Travere’s strategy... Full story

Yahoo Finance • 3 years ago

Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors

FOSTER CITY, Calif., December 19, 2022--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Lon Cardon, Ph.D., FMedSci, to its Board of Directors where he will also serve as a member of the Nomina... Full story